Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Finance
Oncology-focused biopharma reports record product revenues Q2 2004
September 5th, 2004
Cytogen Corp. sshearer@cytogen.com Cytogen Corp. (CYTO), a product-driven, oncology-focused biopharmaceutical company, reported its consolidated financial results for the second quarter and 6 months ended June 30, 2004 and reaffirmed its 2004 full-year financial guidance. Second-quarter sales were strong with total product revenues of $3.9 million for the quarter ended June 30, 2004 compared to $1.7 million for the same period in 2003. For the 6 months ended June 30, 2004, product revenues were $7.5 million compared to $3.6 million for the same period in 2003. Cytogen reported a net loss of $4.4 million, or $0.30 per basic and...
Source: Medical Letter on the CDC & FDA (2004-09-05)
|
